Other

Cypress Pharmaceuticals, Inc.

Cypress Pharmaceutical, Inc.

The Upjohn Co.

American Air Filter Company, Inc.

Hauser-kuhrts, Inc.

Allis-chalmers Corporation

Microdyne Corporation

Burke Pharmaceuticals, Inc.

Charles E Day

Robert L Lewis

Eric H Kuhrts

Paul E Schurr

William A Putman

Robert L Hooper

Kenneth F Wess

Michael S Balbes

Hank S Lin

Provided herein are antimicrobial compositions comprising derivatives of lauric acid, and methods for preparing and using such compositions. As a non-limiting example, a process for preparing an antimicrobial composition may comprise: (1) a saponification step wherein a high-lauric vegetable oil is contacted with a strong base, thereby providing a high-laurate soap component; (2) a lipolysis step wherein a high-lauric vegetable oil is contacted with a lipase, thereby providing a lipolyzed oil composition comprising glycerol monolaurate; and (3) a combination step wherein the soap composition is combined with the lipolyzed oil composition, thereby providing the antimicrobial foaming soap composition.

Antimicrobial compositions derived from high-lauric vegetable oils

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Phosphate-binding magnesium salts and uses thereof

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.

The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.

Phosphate-binding chitosan and uses thereof

An antiflatulent composition is disclosed which comprises a polysaccharide and a preservative. The composition is useful to control gas formation at the site of generation of flatulence.

Antiflatulent composition

Herein is disclosed how to make and to use a nonmetallic antacid composition which is the product of the co-polymerization of guanidine and polyethylenimine. The resultant polymer is useful as an antacid.

Antacid co-polymer of guanidine and polyethylenimine

Disclosed is how to make and to use a genistin-enriched fraction from soy meal. The fraction is prepared by acetone extraction of soy meal, followed by ice-water precipitation. The resulting composition is useful as a pharmaceutical or a dietary supplement for the treatment or prevention of cancer, cardiovascular disease, osteoporosis, or adverse symptoms of menopause in a human.

Genistin-enriched fraction from soy meal

An anion-binding hydrophilic epichlorohydrin and 1-(3-aminopropyl)imidazole copolymeric bile acid sequestrant, pharmaceutical compositions thereof, and use thereof in the treatment of ailments or conditions in which a bile acid sequestrant and inhibitor of fat absorption is indicated.

Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in

The tendency of an orally-ingestible dietary fiber composition to cause excessive flatulence upon oral administration is reduced considerably by the incorporation therein, in addition to other dietary fiber components, a flatulence-reducing amount of chitosan, or by administering such a flatulence-reducing amount of chitosan concurrently with the other dietary fiber components, illustratively the usual antihyperlipidemic pharmaceutical dietary fiber composition or dietary supplement composition. A preferred dietary fiber composition according to the invention incorporates a plurality of dietary fiber components other than chitosan, preferably acacia gum, pectin, and guar gum, together with a flatulence-reducing amount of chitosan.

Prevention of fiber-induced intestinal gas production by chitosan

A method of treating irritable bowel syndrome, including diarrhea, constipation, and pain aspects thereof, in a human patient, whereby the method involves the step of orally administering to the human patient an amount of an anion-binding polymer and a hydrophilic polymer, either simultaneously, concurrently, or in the form of a pharmaceutical composition wherein the anion-binding polymer and the hydrophilic polymer alleviate irritable bowel syndrome.

Method for treatment of irritable bowel syndrome

The application discloses a good-tasting and palatable gritty drug formulation, wherein the grittiness is associated as a part of a pleasurable organoleptic sensation, which contains a gritty and optionally bad-tasting or odoriferous drug and a seedy fibrous fruit, and optionally an aqueous medium and a gelling agent, and preferably also a sweetener and a flavoring agent, wherein the gritty drug is representatively an antihypercholesterolemic drug, especially a bile acid sequestrant, and particularly cholestyramine, a method for the preparation thereof, and a method of converting a gritty drug into a more readily-acceptable formulation which assists with patient compliance.

Good-tasting gritty drug formulations

An orally administrable composition and method for reducing serum cholesterol levels are disclosed. A pharmaceutical composition comprising guar gum, and a dispersing mineral salt such as, for example, calcium carbonate, magnesium carbonate, or potassium carbonate, is administered to humans to reduce serum cholesterol levels.

Growing community of inventors

Leitchfield, KY, United States of America

Charles E Day